FANCI and prostate carcinoma: We recently reported that prostate cancer tumor cells harboring heterozygous deletion of FANCI were selectively eradicated by chemotherapy, while those with intact FANCI resisted chemotherapy, suggesting that FANCI could be a possible therapeutic target to convert resistant cancer cells to eradicable states (26).